9
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Patient-derived xenografts reveal that intraductal carcinoma of the prostate is a prominent pathology in BRCA2 mutation carriers with prostate cancer and correlates with poor prognosis.

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Intraductal carcinoma of the prostate (IDC-P) is a distinct clinicopathologic entity associated with aggressive prostate cancer (PCa). PCa patients carrying a breast cancer 2, early onset (BRCA2) germline mutation exhibit highly aggressive tumours with poor prognosis.

          Related collections

          Author and article information

          Journal
          Eur. Urol.
          European urology
          Elsevier BV
          1873-7560
          0302-2838
          Mar 2015
          : 67
          : 3
          Affiliations
          [1 ] Prostate Cancer Research Group, Department of Anatomy and Developmental Biology, Monash University, Melbourne, Victoria, Australia.
          [2 ] Prostate Cancer Research Group, Department of Anatomy and Developmental Biology, Monash University, Melbourne, Victoria, Australia; Department of Physiology, Monash University, Melbourne, Victoria, Australia.
          [3 ] Tissupath, Mt. Waverley, Victoria, Australia.
          [4 ] kConFab, Research Department, Peter MacCallum Cancer Centre, University of Melbourne, East Melbourne, Victoria, Australia; Familial Cancer Centre, Peter MacCallum Cancer Centre, University of Melbourne, East Melbourne, Victoria, Australia; Division of Cancer Surgery, Peter MacCallum Cancer Centre, University of Melbourne, East Melbourne, Victoria, Australia.
          [5 ] kConFab, Research Department, Peter MacCallum Cancer Centre, University of Melbourne, East Melbourne, Victoria, Australia; Familial Cancer Centre, Peter MacCallum Cancer Centre, University of Melbourne, East Melbourne, Victoria, Australia; Department of Oncology, Peter MacCallum Cancer Centre, University of Melbourne, East Melbourne, Victoria, Australia.
          [6 ] Department of Oncology, Peter MacCallum Cancer Centre, University of Melbourne, East Melbourne, Victoria, Australia; Cancer Genetics Laboratory, Peter MacCallum Cancer Centre, University of Melbourne, East Melbourne, Victoria, Australia.
          [7 ] Department of Oncology, Peter MacCallum Cancer Centre, University of Melbourne, East Melbourne, Victoria, Australia; Bioinformatics, Peter MacCallum Cancer Centre, University of Melbourne, East Melbourne, Victoria, Australia.
          [8 ] Division of Cancer Surgery, Peter MacCallum Cancer Centre, University of Melbourne, East Melbourne, Victoria, Australia; Epworth Research Centre, Epworth Healthcare, Victoria, Australia.
          [9 ] Prostate Cancer Research Group, Department of Anatomy and Developmental Biology, Monash University, Melbourne, Victoria, Australia; Department of Urology, Monash Medical Centre, Monash University, Melbourne, Victoria, Australia.
          [10 ] Prostate Cancer Research Group, Department of Anatomy and Developmental Biology, Monash University, Melbourne, Victoria, Australia; Tissupath, Mt. Waverley, Victoria, Australia.
          [11 ] Department of Urology, University of Melbourne, Austin Hospital, Melbourne Heidelberg, Victoria, Australia. Electronic address: damienmb@unimelb.edu.au.
          Article
          S0302-2838(14)00749-0
          10.1016/j.eururo.2014.08.007
          25154392
          f103e096-a641-4ccc-8c4a-3d7ad3c763cd
          History

          BRCA2 germline mutations,Familial prostate cancer,Intraductal carcinoma,Pathology,Patient-derived xenografts

          Comments

          Comment on this article